A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Phase 3 Active, not recruiting NCT06295692

Condition	Generalized Pustular Psoriasis, Erythrodermic Psoriasis
Phase	Phase 3
Sponsor	Janssen Pharmaceutical K.K.
Status	Active, not recruiting
Enrollment	19 participants
Interventions	JNJ-77242113
Start date	Feb 9, 2024
Completion date	Jan 14, 2025
Results posted	Jan 28, 2026

Summary

The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).

Percentage of Participants With Generalized Pustular Psoriasis (GPP) Who Experienced Treatment Success at Week 16

Week 16 · Percentage of participants

GPP: JNJ-77242113 200 mg QD	88.9 Percentage of participants

Percentage of Participants With Erythrodermic Psoriasis (EP) Who Experience Treatment Success at Week 16

Week 16 · Percentage of participants

EP: JNJ-77242113 200 mg QD	100.0 Percentage of participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis — AbbVie

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский